BCX9930 for the Treatment of C3G, IgAN, and PMN (RENEW)

Status:
Recruiting

Trial end date:
2023-07-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the safety and therapeutic potential of BCX9930 in participants with C3G, IgAN, or PMN.

Phase 2

BioCryst Pharmaceuticals